Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameAim Vaccine
Stock Code06660
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是中國第二大疫苗公司,涵蓋從研發、製造到商業化的整個價值鏈,已商業化八款針對六個疾病領域的疫苗產品,並擁有22款在研疫苗。
Listing Date2022-10-06
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)北京市大興區瀛海鎮鎮區瀛順路16號興海大廈二層218室
Business Address (Hong Kong)香港九龍觀塘道348號宏利廣場5樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteaimbio.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 16.16 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 3,232
Par ValueRMB 1.0 / shares
Offer Period2022-09-23 to 2022-09-28
Global Offering Shares9,714,000 shares
HK Public Offer Shares (Initial)971,600 shares (10.0%)
Public Offer Lots (Initial)4,858lots (Pool A2,429lots,Pool B2,429lots)
International Placing Shares (Initial)8,742,400 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO1,209,713,999 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 156,978,240

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 3,232
2 lots 400 HK$ 6,464
3 lots 600 HK$ 9,696
4 lots 800 HK$ 12,928
5 lots 1,000 HK$ 16,160
6 lots 1,200 HK$ 19,392
7 lots 1,400 HK$ 22,624
8 lots 1,600 HK$ 25,856
9 lots 1,800 HK$ 29,088
10 lots 2,000 HK$ 32,320
15 lots 3,000 HK$ 48,480
20 lots 4,000 HK$ 64,640
25 lots 5,000 HK$ 80,800
30 lots 6,000 HK$ 96,960
35 lots 7,000 HK$ 113,120
40 lots 8,000 HK$ 129,280
45 lots 9,000 HK$ 145,440
50 lots 10,000 HK$ 161,600
100 lots 20,000 HK$ 323,200
150 lots 30,000 HK$ 484,800
200 lots 40,000 HK$ 646,400
250 lots 50,000 HK$ 808,000
300 lots 60,000 HK$ 969,600
400 lots 80,000 HK$ 1,292,800
500 lots 100,000 HK$ 1,616,000
600 lots 120,000 HK$ 1,939,200
900 lots 180,000 HK$ 2,908,800
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,429 lots 485,800 HK$ 7,850,528

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 1.1B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +787%

Valuation & Financials

Market Cap (at Offer Price)HK$ 19,548,978,223
H-Share Market Cap (at Offer Price)HK$ 7,931,733,793
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status2021年虧損人民幣675.9百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201920202021
Revenue 951,6481,637,9701,570,129
Cost of sales -218,803-283,882-275,429
Gross profit 732,8451,354,0881,294,700
Other income and gains, net 26,16340,71453,622
Selling and distribution expenses -330,009-533,249-460,114
Administrative expenses -157,181-198,697-1,167,979
Operating profit 167,542501,627-596,000
Net finance costs -10,781-15,741-10,703
Profit before tax 156,761485,886-606,703
Income tax expense -36,947-85,472-69,170
Profit for the year 119,814400,414-675,873
Profit attributable to owners 117,406379,287-692,774
Balance Sheet
Item 2019202020212022-04
Cash and cash equivalents 318,6391,102,830646,742
Trade and bills receivables 444,838869,8641,063,653
Inventories 228,816252,713367,397
Total current assets 1,346,3082,438,4582,358,684
Total assets 2,950,7224,687,9538,072,353
Total current liabilities 1,190,9691,130,9691,570,042
Total liabilities 1,332,5981,266,3282,373,063
Total equity 1,618,1243,421,6255,699,290
Equity attributable to owners 1,539,3273,421,6254,892,595
Interest-bearing borrowings 283,630173,725591,698933,250
Cash Flow Statement
Item 2019202020212022-04
Net cash from operating activities 327,012250,33193,398
Net cash from investing activities -340,196-604,917-1,337,505
Depreciation of PP&E 63,43772,50687,43032,194
Depreciation of right-of-use assets 12,17121,94023,0718,559
Amortisation of intangible assets 33,83233,89633,79011,283
Purchase of PP&E -314,781-666,683-1,125,381-313,219
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 16.66
First Day OpenHK$ 15.0
First Day Change-83.79%
First Day Volume1170400.0
First Day Turnover18432000.0
Use of Proceeds
1、約60%或42.00百萬港元將分配用于推進我們在研疫苗的研發及持續豐富我 們的疫苗管線; 2、約35%或24.50百萬港元將用于為建設新生產設施的資本開支提供資金; 3、約5%或3.51百萬港元將投入我們的銷售及營銷活動以鞏固及擴大市場領導 地位。

Underwriting Syndicate

Joint Sponsors (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 中信建投(国际)融资有限公司 CE BAU112 MACQUARIE CAPITAL LIMITED CE AAC534
Overall Coordinators (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 中信建投(国际)融资有限公司 CE BAU112 MACQUARIE CAPITAL LIMITED CE AAC534
Joint Bookrunners (9)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 中信建投(国际)融资有限公司 CE BAU112 MACQUARIE CAPITAL LIMITED CE AAC534 BOCI ASIA LIMITED CE AET863 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 招银国际融资有限公司 CE AVM940 富途证券国际(香港)有限公司 CE AZT137 老虎证券(香港)环球有限公司 CE BMU940
Joint Lead Managers (10)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 中信建投(国际)融资有限公司 CE BAU112 MACQUARIE CAPITAL LIMITED CE AAC534 BOCI ASIA LIMITED CE AET863 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 招银国际融资有限公司 CE AVM940 富途证券国际(香港)有限公司 CE AZT137 老虎证券(香港)环球有限公司 CE BMU940 Livermore Holdings Limited CE BJN764

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman周延—
Company Secretary劉靈、林穎芝—
No director data available.

Major Shareholders

Major Shareholders & Holdings周延先生直接持有200,000,000股內資股(16.67%),並通過西藏赤誠之心及眾人行持有額外權益;西藏赤誠之心持有200,000,000股內資股;西藏盈豐持有44,300,000股內資股及55,700,000股H股。
About this page

This page shows Aim Vaccine (06660) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect